Our Blog

17
Mar

Cancer Test Profile

Comparing testing methods for type of cancers in 2015

IVDNewsTM captures data from around the world on methods used to detect, monitor and provide prognosis on a variety of cancers – both somatic driven and germ cell or genetic based. As the methods or technology change there is always an adoption phase and medical practice phase driven by regional dynamics of cancer (e.g., incidence, government funding, private insurance).

The table below is a comparison of the methods used to identify two groups of cancers and those cancers that are under investigation using the newer miRNA methods. The comparison is made based on the number of publications captured in IVDNewsTM for 1H 2015 and 2H 2015. Analysis of the publications can identify a number of key marketing parameters, some of the parameters include:

  • name and location of facilities involved with specific biomarkers (geographic segmentation)
  • trends in testing methods
  • KOL’s by country or region
  • sales leads by region or country
  • differences in medical practice by regions and
  • differences in clinical issues by regions

Groups are divided in IVDNewsTM with Topics as follows:
Group 1 – Prostate, Lung, Breast, Colon, Cervical, and Ovarian cancer
Group 2 – Thyroid, Liver, Bladder, Renal, Melanoma, Pancreatic, Kidney, other minor cancers
Group 3 – Special category for all solid tumor cancers using miRNA methods

Period Method

Journals

Abstracts

Press releases

Total #

1H 2015          
Group 1

 

Immuno

Molecular

107

201

98

335

23

88

228

624

Group 2 Immuno

Molecular

70

97

70

160

11

45

151

302

Group 3 Only Molecular

103

66

6

175

           
2H 2015          
Group 1 Immuno

Molecular

111

248

58

282

23

114

192

644

Group 2 Immuno

Molecular

57

87

74

124

10

32

141

243

Group 3 Only Molecular

95

46

6

147

An example of using the data is comparing methods by types of cancers in Asiatic Countries versus Germany. Journals and abstracts invariably identify the author, institutions and location as well as email contacts in a number of cases.

For cancers Thyroid, Liver, Bladder, Renal, Melanoma, Kidney and Pancreatic

Total 2015

Method

Germany

China

Japan

Korea

Immuno

9

47

25

13

Molecular

18

24

27

21

Even though the number of molecular publications for these cancers in 2015 was significantly larger than immuno methods (545 to 292), the use of immuno methods was still larger than molecular methods (85 to 72) in the 3 Asian countries. When the largest EU Country, Germany, is compared to the Asian countries the use of molecular methods (18) is not significantly less than any of the Asian countries given the huge difference in population. However, when comparing immuno methods there is a significant difference as immuno is still the dominant technology for the Asian countries.

These data would point that for the near term the market for immunoassays for these cancers will be in the Asian countries.

Consider using the IVDNewsTM data base via the Data Analysis Reports (DARs) to obtain a variety of market and technology metrics to support R&D, Business Development and Marketing strategies and plans.

10
Mar

Recent History of Acquisitions and IPOs for Reference Labs

Recent History of Acquisitions and IPOs for Reference Labs and Companies Developing or Marketing Molecular Products

Laboratory versus Molecular Company Acquisition/IPO comparison

The table below shows the recent activity in the reference laboratory and corporate world. Prior to 2013 the activity in the Reference Laboratory Industry was pretty well limited to acquisitions of labs by labs capturing market share. Starting late 2012 this began to change as acquisitions and IPOs for labs were for molecular methods and content to expand into new market segments.

  2013 2014 2015 TOTAL
IPO        
LAB 3 3 4 10
COMPANY 1 4 3 8
ACQUISITIONS/MERGER        
LAB

a) by another lab

b) by a company

 

3

2

 

5

2

 

8

4

 

16

8

  5 7 12 24
COMPANY – molecular 4 9 14 27

Note: In the US the two largest reference labs embarked on a different growth strategy beginning in late 2013:

LabCorp   – 2/2014     Acquired Covance CRO

-11/2014     Acquired Bode – forensic testing business

-10/2015     Acquired Food testing business

Quest Diagnostics

-4/2015         Merger with Quintiles CRO

Further, both labs are focusing on partnerships with Hospitals to manage their laboratory testing services. A reasonable interpretation is these two labs do not expect growth via market expansion within the US clinical diagnostic segment. Outside the US lab acquisitions, principally in Europe, as consolidation continues to capture market share.

On the corporate side several firms changed their business model from manufacturer to laboratory services which mirrors the trend toward specialized content (Exact Sciences, Vermillion, Transgenomics, Sequenom, Cancer Genetics) and several set up via acquisition or partnerships laboratory services (Sysmex, Roche, Illumina, Opko, Premaitha, Diaxonhit). Again these were focused on content.

Finally, CareDx changed to laboratory services then acquired a product company, bioMerieux sold most of its shareholdings in its lab business bioTheranostics, and Beckman sold its testing laboratory.

A key theme for all the reference lab activity is the value of content. Laboratories that have ‘generic’ testing menus have struggled to obtain financing and a couple ceased operations. All but two IPOs were associated with a unique biomarker and clinical content was king. The two labs that were not based on content had strong market segment presence in a selected geography – India and Middle East respectively.

 

Meanwhile, as reported in IVDNews Molecular Deal reports, the number of lab and company private financing arrangements were multiple times larger than the IPO and acquisitions announced during the last 3 years. There were well over 100 private financing deals during this period. With the decelerating global economic financial measures reported on a regular basis, 2016/17 could be a watershed period for consolidation as privately financed entities are shut out of external financing channels and will need to find an acquirer.

10
Mar

Acquisitions

ACQUISITION DETAILS   2010- 2015

In the February 25th IVDNews™ issue, data was provided on the number of acquisitions that had been announced since 2010. In this period there were 226 companies that had been acquired.

In the table below is a further breakout of the type of acquisition by year. Molecular was the dominant type of acquisition with 80 (35%) followed by POC with 39 (17%). The remaining acquisitions were a mixture of immunoassay based firms, distribution firms, and other categories of firms not using immunoassay methods (e.g., microbiology, chemistry, diabetes).

AD1015

As the number of acquisitions has continued the number of firms that are available to be acquired has shrunk, especially those with at least $50M in sales. If the sales threshold is raised to $100M in sales but less than $500M the number of available firms is less than 20. Interestingly a number of CEO’s and CFO’s of the larger diagnostic firms have commented during recent conference calls, the price of diagnostic assets has risen. This could be directly related to the smaller number of mid sized firms that could be acquired.

Looking ahead one could speculate that the number of acquisitions in 2016 could drop significantly from recent years as the available field has shrunk.

6
Feb

BUILD YOUR OWN LIBRARY OF IMPORTANT ARTICLES

IVDNews

IVDNews

AVOID HOURS PER MONTH TRYING TO SET UP FILES ON COMPANIES OR PRODUCTS

Build a library of important articles without cutting, pasting, filing and without loss of tables or graphs?
All steps are done electronically with key strokes

  • You have access to saved articles 365/24/7 whether at a congress, regional meeting, customer laboratory, or just in your office. Just enter your U/N and P/W at ivdnews.net and access your files
  • Add comments to an article on why you selected the article
  • Transfer Library to another email address when employee leaves or is assigned a different job – you never lose the files.
  • Avoid losing files when stored on computer that crashes or ceases to function

Activate the IVDNews Personal Library option.

No CUT, PASTE, TRANSFER TO FILE, and 365/24/7 ACCESSIBLE.

All steps are done electronically with key strokes

Click the link to see how easy it is to use – http://ivdnews.com/PL14.pdf

Contact IVDNews™ on activating option at editor@ivdnews.com

4
Feb

“Knowledge is power” – Francis Bacon 1597

3
Feb

Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!